AAAAAA
Results:
1-16
|
Results: 16
Authors:
Piro, M
Zeldow, PB
Knight, SJ
Mytko, JJ
Gradishar, WJ
Citation: M. Piro et al., The relationship between agentic and communal personality traits and psychosocial adjustment to breast cancer, J CL P MED, 8(4), 2001, pp. 263-271
Authors:
Gradishar, WJ
Stephenson, P
Glover, DJ
Neuberg, DS
Moore, MR
Windschitl, HE
Piel, I
Abeloff, MD
Citation: Wj. Gradishar et al., A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma - An Eastern Cooperative Oncology Group Study (E8188), CANCER, 92(10), 2001, pp. 2517-2522
Authors:
Carlson, RW
Anderson, BO
Bensinger, W
Cox, CE
Davidson, NE
Edge, SB
Farrar, WB
Goldstein, LJ
Gradishar, WJ
Lichter, AS
McCormick, B
Nabell, LM
Reed, EC
Silver, SM
Smith, ML
Somlo, G
Theriault, R
Ward, JH
Winer, EP
Wolff, A
Citation: Rw. Carlson et al., NCCN Practice Guidelines for breast cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 33-49
Authors:
Gradishar, WJ
Soff, G
Liu, JG
Cisneros, A
French, S
Rademaker, A
Benson, AB
Bouck, N
Citation: Wj. Gradishar et al., A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients, ONCOL-BASEL, 58(4), 2000, pp. 324-333
Authors:
Noe, LL
Becker, RV
Gradishar, WJ
Gore, M
Trotter, JP
Citation: Ll. Noe et al., The cost effectiveness of tamoxifen in the prevention of breast cancer, AM J M CARE, 5(6), 1999, pp. S389-S406
Authors:
O'Regan, R
Jordan, VC
Gradishar, WJ
Citation: R. O'Regan et al., Tamoxifen and contralateral breast cancer, J AM COLL S, 188(6), 1999, pp. 678-683
Authors:
Carlson, RW
Anderson, BO
Bensinger, W
Cox, C
Davidson, NE
Edge, SB
Farrar, WB
Goldstein, LJ
Gradishar, WJ
Lichter, AS
Mccormick, B
Nabell, LM
Reed, EC
Silver, SM
Smith, MLP
Somlo, G
Theriault, RL
Winer, EP
Citation: Rw. Carlson et al., Update: NCCN practice guidelines for the treatment of breast cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 187-212
Authors:
Gradishar, WJ
Lurie, RH
Citation: Wj. Gradishar et Rh. Lurie, Formulating guidelines for chemotherapy in advanced breast cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 231-235
Authors:
Gradishar, WJ
Jordan, VC
Citation: Wj. Gradishar et Vc. Jordan, Hormonal therapy for breast cancer - An update, HEMAT ONCOL, 13(2), 1999, pp. 435
Authors:
Sparano, JA
Speyer, J
Gradishar, WJ
Liebes, L
Sridhara, R
Mendoza, S
Fry, D
Egorin, MJ
Citation: Ja. Sparano et al., Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer, J CL ONCOL, 17(3), 1999, pp. 880-886
Authors:
Hensley, ML
Schuchter, LM
Lindley, C
Meropol, NJ
Cohen, GI
Broder, G
Gradishar, WJ
Green, DM
Langdon, RJ
Mitchell, B
Negrin, R
Szatrowski, TP
Thigpen, JT
Von Hoff, D
Wasserman, TH
Winer, EP
Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Authors:
Gradishar, WJ
Citation: Wj. Gradishar, High-dose chemotherapy and breast cancer, J AM MED A, 282(14), 1999, pp. 1378-1380
Authors:
Gradishar, WJ
Citation: Wj. Gradishar, Recently initiated studies: Neoadjuvant treatments in the next century, SEMIN ONCOL, 26(1), 1999, pp. 26-29
Authors:
Morrow, M
Jordan, VC
Takei, H
Gradishar, WJ
Pierce, LJ
Citation: M. Morrow et al., In brief, CURR P SURG, 36(3), 1999, pp. 158-216
Authors:
Gradishar, WJ
Jordan, VC
Citation: Wj. Gradishar et Vc. Jordan, Pharmacology and use of antiestrogens in treatment and chemoprevention of breast cancer, CONT ENDOC, 11, 1999, pp. 283-311
Authors:
Gradishar, WJ
Citation: Wj. Gradishar, Endpoints for determination of efficacy of antiangiogenic agents in clinical trials, CANC DRUG, 3, 1999, pp. 341-353
Risultati:
1-16
|